Use of a combination of the virus-neutralizing monoclonal antibodies casirivimab and imdevimab for mild to moderate COVID-19 in patients at high risk of progression: Results of the non-interventional observational study

Use of a combination of the virus-neutralizing monoclonal antibodies casirivimab and imdevimab for mild to moderate COVID-19 in patients at high risk of progression: Results of the non-interventional observational study

Aim. To evaluate the efficacy and safety of a combination of virus-neutralizing monoclonal antibodies MAB (casirivimab and imdevimab) in patients with mild to moderate COVID-19 with risk factors in real word settings. Materials and methods. A non-interventional non-comparative observational stud...

Full description

Bibliographic Details
Main Authors: Marina S. Lebedkina, Daria S. Fomina, Zinaida Y. Mutovina, Ulyana A. Mаrkina, Pavel O. Bogomolov, Vladimir P. Chulanov, Mariana A. Lysenko, Ekaterina I. Alexeeva
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2023-08-01
Series:Терапевтический архив
Subjects:
covid-19
casirivimab/imdevimab
efficiency
safety
Online Access:https://ter-arkhiv.ru/0040-3660/article/viewFile/516486/pdf

Internet

https://ter-arkhiv.ru/0040-3660/article/viewFile/516486/pdf

Similar Items